BACKGROUND: Fosbretabulin is a novel vascular-disrupting agent that has antitumor activity against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a phase I trial. This phase II study determined the efficacy and safety of fosbretabulin in patients with advanced ATC and whether fosbretabulin altered the natural history of ATC by virtue of doubling the median survival. A secondary aim evaluated the prognostic value of serum soluble intracellular adhesion molecule-1 (sICAM). METHODS: Twenty-six patients received fosbretabulin 45 mg/m(2) as a 10-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle. sICAM levels were obtained at baseline, over the first two cycles, and end of therapy. Treatment was continued until disease progression. RESULTS: Fosbretabulin was well tolerated; grade 3 toxicity was observed in nine patients (35%), and grade 4 toxicity in one (4%). QTc prolongation delayed treatment in four causing one to stop treatment. Median survival was 4.7 months with 34% and 23% alive at 6 and 12 months, respectively. Median duration of stable disease in seven patients was 12.3 months (range, 4.4-37.9 months). Baseline serum sICAM levels were measured in 24 patients with a median 253.5 ng/mL. There was a significant difference in event-free survival among tertiles of baseline sICAM levels (p < 0.009). CONCLUSIONS: There were no objective responses seen with single-agent fosbretabulin as administered in this trial, and we did not observe a doubling of survival as our primary endpoint. This is among the largest prospective trials ever conducted for ATC. Fosbretabulin has an acceptable safety profile in patients with advanced ATC, and one-third survived more than 6 months. Despite a small sample size, low baseline sICAM levels were predictive of event-free survival. Further prospective validation of sICAM as a therapeutic biomarker and exploring combination regimens with fosbretabulin are warranted.
BACKGROUND:Fosbretabulin is a novel vascular-disrupting agent that has antitumor activity against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a phase I trial. This phase II study determined the efficacy and safety of fosbretabulin in patients with advanced ATC and whether fosbretabulin altered the natural history of ATC by virtue of doubling the median survival. A secondary aim evaluated the prognostic value of serum soluble intracellular adhesion molecule-1 (sICAM). METHODS: Twenty-six patients received fosbretabulin 45 mg/m(2) as a 10-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle. sICAM levels were obtained at baseline, over the first two cycles, and end of therapy. Treatment was continued until disease progression. RESULTS:Fosbretabulin was well tolerated; grade 3 toxicity was observed in nine patients (35%), and grade 4 toxicity in one (4%). QTc prolongation delayed treatment in four causing one to stop treatment. Median survival was 4.7 months with 34% and 23% alive at 6 and 12 months, respectively. Median duration of stable disease in seven patients was 12.3 months (range, 4.4-37.9 months). Baseline serum sICAM levels were measured in 24 patients with a median 253.5 ng/mL. There was a significant difference in event-free survival among tertiles of baseline sICAM levels (p < 0.009). CONCLUSIONS: There were no objective responses seen with single-agent fosbretabulin as administered in this trial, and we did not observe a doubling of survival as our primary endpoint. This is among the largest prospective trials ever conducted for ATC. Fosbretabulin has an acceptable safety profile in patients with advanced ATC, and one-third survived more than 6 months. Despite a small sample size, low baseline sICAM levels were predictive of event-free survival. Further prospective validation of sICAM as a therapeutic biomarker and exploring combination regimens with fosbretabulin are warranted.
Authors: Willem J van Heeckeren; Shyam Bhakta; Jose Ortiz; Jeff Duerk; Matthew M Cooney; Afshin Dowlati; Keith McCrae; Scot C Remick Journal: J Clin Oncol Date: 2006-04-01 Impact factor: 44.544
Authors: Afshin Dowlati; Kelly Robertson; Tomas Radivoyevitch; John Waas; Nicholas P Ziats; Paul Hartman; Fadi W Abdul-Karim; Jay K Wasman; Jack Jesberger; Jonathan Lewin; Keith McCrae; Percy Ivy; Scot C Remick Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Loïc Vincent; Pouneh Kermani; Lauren M Young; Joseph Cheng; Fan Zhang; Koji Shido; George Lam; Heidi Bompais-Vincent; Zhenping Zhu; Daniel J Hicklin; Peter Bohlen; David J Chaplin; Chad May; Shahin Rafii Journal: J Clin Invest Date: 2005-10-13 Impact factor: 14.808
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Renaud De Crevoisier; Eric Baudin; Anne Bachelot; Sophie Leboulleux; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Joshua H Bilenker; Keith T Flaherty; Mark Rosen; Lisa Davis; Maryann Gallagher; James P Stevenson; Weijing Sun; David Vaughn; Bruce Giantonio; Ross Zimmer; Mitchell Schnall; Peter J O'Dwyer Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Keith C Bible; Vera J Suman; Michael E Menefee; Robert C Smallridge; Julian R Molina; William J Maples; Nina J Karlin; Anne M Traynor; Priya Kumar; Boon Cher Goh; Wan-Teck Lim; Ayoko R Bossou; Crescent R Isham; Kevin P Webster; Andrea K Kukla; Carolyn Bieber; Jill K Burton; Pamela Harris; Charles Erlichman Journal: J Clin Endocrinol Metab Date: 2012-07-06 Impact factor: 5.958
Authors: Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-09 Impact factor: 11.908
Authors: R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling Journal: J Clin Endocrinol Metab Date: 2013-04-15 Impact factor: 5.958